I. Purpose

This policy outlines situations and circumstances where significant changes to an IACUC protocol may be handled administratively, without Full Committee Review (FCR) or Designated Member Review (DMR), in compliance with NIH and USDA guidance.

II. Regulatory or Accreditation Authority

The PHS Policy on Humane Care and Use of Laboratory Animals (Policy) (IV.C.1.) and Animal Welfare Regulations (9 CFR 2.31 (d) (1) (i)-(iv)) define the responsibilities of the IACUC regarding review and approval of proposed significant changes to animal activities. Changes to approved research projects must be conducted in accordance with the institution’s Assurance, the United States Department of Agriculture (USDA) Animal Welfare Act and Animal Welfare Regulations and must be consistent with the Guide unless an acceptable justification for a departure is presented. Additionally, IACUCs are responsible for assuring that the changes to approved animal activities meet the requirements described in the PHS Policy IV.C.1.a-g

III. Scope

This policy applies to the review of IACUC protocols with significant changes using Veterinary Verification and Consultation (VVC).

IV. Policy

Some significant changes to an IACUC protocol may be handled administratively by IACUC staff in consultation with a LARC or IACUP veterinarian. These changes must be made in accordance with an existing IACUC or LARC approved guideline, procedure, or policy, and meet the criteria listed in B. and C. below, as determined by a LARC or IACUP veterinarian.

A. Veterinarian Authority

The LARC or IACUP veterinarian has the authority to request IACUC review of proposed changes for any reason, and must request IACUC review for any changes which do not meet the parameters of this policy. The veterinarian is the subject matter expert who determines that the change meets IACUC policies and does not require committee review.

B. Significant Changes
Regulators at NIH and USDA define Significant Changes in animal protocols as those that have, or have the potential to have, a negative impact on animal welfare; on human health and safety; or some other matters, such as changes that may actually increase animal welfare, or changes in Principal Investigator.

Significant changes may be approved without Full Committee or Designated Member review in the following areas:

1) Changes to compounds or dosage of Anesthesia, Analgesia, Sedation, Veterinary Therapeutics, or Experimental Substances. Examples of changes which may be approved under this category using agents listed in the Reference below are:

   a. A change in dosage, route, frequency, or duration within acceptable and known veterinary parameters;
   b. Addition of or change in analgesic, anesthetic, sedative agent, or veterinary therapeutic agent, or experimental substances which are not expected to increase pain or distress, impact the approved endpoint criteria, or impact the approved personnel safety considerations;
   c. Changes in substances that are the same class of compounds (ex. novel peptides, chemotherapeutic drugs) currently approved in the protocol and which are not expected to increase pain or distress, impact the approved endpoint criteria, or impact the approved personnel safety considerations;
   d. Changes in substances that are different types of compounds than those currently approved in the protocol but which are not expected to change the objectives of the study, increase pain or distress, impact the approved endpoint criteria, or impact the approved personnel safety considerations - examples of the type of compounds includes: antibiotics, colloidal fluids, diluents/ vehicles (e.g., DMSO, diluted ethanol, corn oil, peanut oil, sesame seed oil, commonly formulated physiologic saline and buffer solutions, distilled water), imaging contrast agents, gene expression modulators (e.g., tamoxifen, tetracycline), etc. with published doses referenced in materials listed above for “Anesthesia, analgesia, or sedation;”
   e. Injection with new tumor cell lines provided the tumor size and condition endpoints are consistent with the originally approved protocol but which are not expected to increase pain or distress, impact the approved endpoint criteria, or impact the approved personnel safety considerations.

2) Use of non-pharmaceutical-grade substances, when pharmaceutical-grade alternatives are not available, for the following reasons:

   a. An equivalent veterinary or human pharmaceutical-grade compound does not exist or it is unavailable;
   b. The equivalent veterinary or human pharmaceutical-grade compound is not available in the appropriate formulation or concentration required;
   c. Although there is an equivalent veterinary or human drug available, the chemical grade is required to replicate methods from previous studies;
d. The equivalent veterinary or human pharmaceutical-grade compound contains preservatives or inactive ingredients which may confound the research goals of the study.

3) Changing euthanasia method to any method approved in the AVMA guidelines.

4) Changes in duration, frequency, number, and type of procedures performed. Typical examples under this category may include:
   a. Changing an already approved procedure on the protocol in terms of its duration, frequency, number, or type consistent with IACUC and LARC policies, guidelines, and standard procedures;
   b. Changes in experimental timeline (e.g., resulting from unanticipated delays) that do not negatively impact animal welfare and health. Approved monitoring, humane endpoints and associated documentation are required, when applicable, during periods of delay;
   c. Changing a surgery from survival to non-survival.

5) Change to animals of a different sex.

6) Addition of another strain or breed of the same species.

7) Increasing the number of non-USDA regulated animals approved for study by up to 10%.

C. Changes Requiring IACUC Approval

Changes which would otherwise fit under the categories listed above in accordance with IACUC policies, procedures, or guidelines may still require IACUC committee review. A proposed change requires IACUC review by either DMR or FCR if it:

1) Is expected to result in greater pain, distress, degree of invasiveness, or mortality;
2) Changes the study objectives;
3) Impacts personnel safety;
4) Changes the Principal Investigator (PI);
5) Changes housing to a location that is not currently overseen for animal use;
6) Changes a surgery from non-survival to survival surgery; or,
7) Changes study species.

D. IACUC Notification of administrative approval of significant changes

Principal Investigators receive a standard Approval letter. The RIO software contains a report function that lists all protocols by their method of approval, including protocols approved administratively with veterinary consultation.

V. References

a. NIH Guidance on Significant Changes to Animal Activities, NOT-OD-14-126
b. LARC Veterinarians’ Anesthesia and Analgesia Recommendations for UCSF Laboratory Animals
d. Richard E. Fish, Peggy J. Danneman, Marilyn Brown, and Alicia Z. Karas, eds.  

e. "Primate Formulary", University of California, Davis


h. "Nonhuman Primate Formulary", Association of Primate Veterinarians,


